By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm William Blair said today it has initiated coverage of Illumina's stock, giving it an "outperform" rating.

It also gave San Diego-based Illumina an "aggressive growth" company profile. Amanda Murphy, an analyst at William Blair, estimated a $1.06 earnings per share price for 2010, a $1.46 EPS for 2011, and a $1.93 EPS for 2012.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.